Log In
Print this Print this

DBT-1339, MDR-1339

  Manage Alerts
Collapse Summary General Information
Company Medifron DBT Co. Ltd.
DescriptionBeta amyloid inhibitor
Molecular Target Beta amyloid
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerDaewoong Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today